Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-02-20
2007-02-20
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S208100, C530S300000, C530S350000
Reexamination Certificate
active
09877606
ABSTRACT:
The present invention provides polypeptides comprising a stabilized trimer of the carboxyl-terminal core region of the ectodomain of an enveloped virus, such as HIV. A subject polypeptide comprises three monomers that form a trimeric coiled coil in a prefusogenic conformation of an enveloped virus such as HIV. The subject polypeptides are useful as vacciness against enveloped virus, such as HIV, which vaccines are also provided. The present invention also provides methods of vaccinating an individual to prevent or treat HIV infection or prevent or treat infection by another enveloped virus, using a subject vaccine. Antibodies or binding portions thereof raised against a C-terminus trimeric coiled coil motif of an HIV gp41 ectodomain, or carboxyl-terminal core region of the ectodomain of another enveloped virus, are also provided as are methods of making such antibodies. Methods for detecting HIV or other enveloped viruses in a sample, as well as methods of screening for drugs which can inhibit HIV infection or other enveloped virus infection, are also provided by the present invention.
REFERENCES:
patent: 5643756 (1997-07-01), Kayman et al.
patent: 5654195 (1997-08-01), Sodroski et al.
patent: 5714577 (1998-02-01), Montelaro et al.
patent: 5854037 (1998-12-01), Palese et al.
patent: 0679187 (1994-01-01), None
patent: WO-99/16883 (1999-04-01), None
Lu, M., et al. (1995) “A trimeric structural domain of the HIV-1 transmembrane glycoprotein,”Nature Structural Biology,vol. 12:1075-1082.
Blacklow, S.C., et al. (1995) “A Trimeric Subdomain of the Simian Immunodeficiency Virus Envelope Glycoprotain,”Biochemistry,vol. 34(46):14955-14962.
Lu, M., et al. (1997) “A Trimeric Structural Subdomain of the HIV-1 Transmembrane Glycoprotein,”Journal of Biomolecular Structure&Dynamics,vol. 15(3):465-471.
Chen, C.H., et al. (1995) “A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives: Implication for Viral Fusion,”Journal of Virology,3771-3777.
Tan, K., et al. (1997) “Atomic Structure of a thermostable subdomain of HIV-1 gp41,”Proc. Natl. Acad. Sci. USA,vol. 94:12303-12308.
Salzwedel, K., et al. (1999) “A Conserved Tryptophan-Rich Motif in the Membrane-Proximal Region of the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Is Important for Env-Mediated Fusion and Virus Infectivity,”Journal of Virology,vol. 73(3):2469-2480.
Jiang, et al. (1993) “HIV-1 inhibition by a peptide” and “Nested fullerene-like structures,”Scientific Correspondence,vol. 365:113.
Malashkevich, V.N., et al. (1998) “Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides,”Proc. Natl. Acad. Sci. USA,vol. 95:9134-9139.
Wild, C.T., et al. (1994) “Peptides corresponding to a predictive -helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection,”Proc. Natl. Acad. Sci USA,vol. 91:9770-9774.
Gallaher, W.R., et al. (1989) “A General Model for the Transmembrane Proteins of HIV and Other Retroviruses,”AIDS Research and Human Retroviruses,vol. 5(4):431-440.
Chambers, P., et al. (1990) “Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins,”Journal of General Virology,71:3075-3080.
Wild, C., et al. (1995) “The Inhibitory Activity of an HIV Type 1 Peptide Correlates with Its Ability to Interact with a Leucine Zipper Structure,”AIDS Research and Human Retroviruses,vol. 11(3):323-325.
Delwart, E.L., et al. (1990) “Retroviral Envelope Glycoproteins Contain a ‘Leucine Zipper’-like Repeat,”AIDS Research and Human Retroviruses,vol. 6(6):703-706.
Neurath, A.R., et al. (1995) “Two Partially Overlapping Antiviral Peptides from the External Portion of HIV Type 1 Glycoprotein 41, Adjoining the Transmembrane Region, Affect the Glycoprotein 41 Fusion Domain,”AIDS Research and Human Retroviruses,vol. 11(2):189-190.
Chan, D.C., et al. (1997) “Core Structure of gp41 from the HIV Envelope Glycoprotein,”Cell,vol. 89:263-273.
Caffrey, et al. (1998) “Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41,”The EMBO Journal,vol. 17(16):4572-4584.
Yang, X., et al. (2000) “Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution,”Journal of Virology,vol. 74(10):4746-4754.
Yang, Z.N., et al. (1999) “The Crystal Structure of the SIV gp41 Ectodomain at 1.47 A Resolution,”Journal of Structural Biology,126:131-144.
Weissenhorn, W., et al. (1997) “Atomic structure of the ectodomain from HIV-1 gp41,”Nature,vol. 387(22):426-430.
Blacklow, Stephen.C. ,et al. ,“A Trimeric Subdomain of the Simian Immunodeficiency Virus Envelope Glycoprotein”,Biochemistry,(1995),14955-14962.
Chan, David.C. ,et al. ,“Core Structure of gp41 from the HIV Envelope Glycoprotein”,Cell,(Apr. 1997),263-273.
Chan, David.C. ,et al. ,“Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target”,Proceedings of the National Academy of Sciences of the United States of America,(Dec. 1998),15613-15617.
Chen, Chin-Ho.,et al. ,“A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives: Implication for Viral Fusion”,Journal of Virology,(Jun. 1995),3771-3777.
Furuta, Rika.A. ,et al. ,“Capture of an early fusion-active conformation of HIV-1 gp41”,Nature Structural Biology,(Apr. 1998),276-279.
Kilby, J.M. ,et al. ,“Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry”,Nat Med,(Nov. 1998),Abstract.
Lawless, M.K. ,et al. ,“HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41”,Biochemistry,(Oct. 1996),Abstract.
Lawless, M.K. ,et al. ,“Quantitation of a 36-amino-acid peptide inhibitor of HIV-1 membrane fusion in animal and human plasma using high-performance liquid chromatography and fluorescence detection”,J Chromatogr&Biomed Sci Appl,(Apr. 1998),Abstract.
Lu, Min.,et al. ,“A trimeric structural domain of the HIV-1 transmembrane glycoprotein”,Nature Structural Biology,(Dec. 1995),1075-1082.
Rabenstein, Mark.,et al. ,“A Peptide from the Heptad Repeat of Human Immunodeficiency Virus gp41 Shows both Membrane Binding and Coiled Coil Formation”,Biochemistry,(1995),13390-13397.
Shu, Wei.,et al. ,“Trimerization Specificity in HIV-1 gp41: Analysis with a GCN4 Leucine Zipper Model”,Biochemistry,(1999),5378-5385.
Shurgas, Diane.C. ,et al. ,“Biophysical Characterization of Recombinant Proteins Expressing the Leucine Zipper-Like Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41”,Journal of Virology,(May 1996),2982-2991.
Tan, Kemin.,et al. ,“Atomic structure of a thermostable subdomain of HIV-1 gp-42”,Proceedings of the National Academy of Sciences of the United States of America,(Nov. 1997),12303-12308.
Vazquez, Maria-Isabel.,et al. ,“The Vaccinia Virus 14-Kilodalton (A27L) Fusion Protein Forms a Triple Coiled-Coil Structure and Interacts with the 21-Kilodalton (A17L) Virus Membrane Protein through a C-Terminal a-Helix”,Journal of Virology,(Dec. 1998),10126-10137.
Weissenhorn, Winfried.,et al. ,“Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 gp41 ectodomain expressed inEscherichia coli”, Proceedings of the National Academy of Sciences of the United States of America,(Jun. 1997),6065-6069.
Weissenhorn, W.,et al. ,“Atomic structure of the ectodomain from HIV-1 gp41”,Nature,(May 1997),42
Ji Hong
Lu Min
Cornell Research Foundation Inc.
Parkin Jeffrey S.
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Antigen for developing neutralizing antibodies to human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen for developing neutralizing antibodies to human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen for developing neutralizing antibodies to human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3856293